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Objective: This post hoc analysis evaluated the efficacy and safety of triple therapy with 
amlodipine/valsartan+hydrochlorothiazide (Aml/Val+HCTZ) vs dual therapy with Aml+HCTZ 
in stage 2 hypertensive patients.
Methods: The analysis included patients from an eight-week, multicenter, double-blind study, 
randomized to Aml/Val 10/160 mg or Aml 10 mg groups, who received add-on HCTZ 12.5 mg 
at week 4 if mean sitting systolic blood pressure (msSBP) was .130 mmHg.
Results: Of the patients receiving Aml/Val+HCTZ and Aml+HCTZ, 98% (N = 133/136) and 
96% (N = 200/208) completed the study, respectively. Baseline characteristics were similar 
across groups (Caucasians, 80.2%; diabetics, 14.8%; age, 58.6 years [28.2% $ 65 years]; body 
mass index, 31 kg/m2; mean sitting blood pressure (msBP), 171.5/95.5 mmHg [18% msSBP   
$ 180 mmHg]). Aml/Val+HCTZ provided significantly greater msBP reductions from base-
line to week 8 than Aml+HCTZ (30.5/13.8 vs 24.3/8.3 mmHg, P , 0.0001). The incremental 
msBP reduction (week 4 to 8) with HCTZ added to Aml/Val was greater than when added to 
Aml (6.9/3.5 vs 3.1/1.0 mmHg, P , 0.01). Treatments were well tolerated with similar overall 
incidence of adverse events (Aml/Val+HCTZ: 33.8%, Aml+HCTZ: 33.2%).
Conclusion: Aml/Val+HCTZ provided significantly greater BP reductions than Aml+HCTZ 
in patients with stage 2 hypertension. Aml/Val+HCTZ triple therapy may be a suitable option 
for patients requiring more than two agents to reach target BP.
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Introduction
Hypertension is a major risk factor for cardiovascular events and mortality.1,2 Despite 
this awareness, blood pressure (BP) control rates remain low, varying from 5% to 
33%.3–5 Thus, effective treatment strategy and management of hypertension are 
imperative.
Being a multifactorial disease, management of hypertension often requires mul-
tiple drugs. In patients whose BP is $ 20/10 mmHg above the goal, the use of two 
antihypertensive agents is recommended as an initial therapy.1 Combining drugs 
with complimentary modes of action is pragmatic, as it is more likely to achieve 
better BP control and it also attenuates the adverse events (AEs) of the constituent 
monotherapies.6,7 Furthermore, the risk of non-compliance, one of the major reasons for Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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failure of antihypertensive therapy, is reduced by 24%–26% 
with use of single pill combination regimens.8
Despite the availability of numerous dual drug combina-
tions, BP largely remains uncontrolled, more so in the elderly, 
black, diabetic, obese, and severely hypertensive patients.9–11 
Clinical trials including ALLHAT, ACCOMPLISH, INVEST, 
and LIFE have reported that 23%–52% patients require 
three or more antihypertensive agents for BP control and 
target-level maintenance (,140/90 or ,130/80 mmHg 
depending on cardiovascular risk).5,12–16 Thus, a triple drug 
combination therapy would be a desirable treatment option 
for hypertension.
In a previously reported study by Destro et al, patients 
with stage 2 hypertension, initially randomized to a regimen 
of dual therapy with amlodipine (Aml)/valsartan (Val) had 
greater reductions in BP than patients randomized to Aml 
monotherapy after 4 weeks.17 In this study, hydrochlorothi-
azide (HCTZ) was added as a third agent at week 4 if the 
patients were unable to achieve a target BP level, defined as a 
mean sitting systolic blood pressure (msSBP) , 130 mmHg. 
In this report, we present results of secondary analyses of 
this study examining the subgroup of patients who required 
HCTZ add-on therapy to assess the benefits of the triple com-
bination with Aml/Val+HCTZ compared with Aml+HCTZ 
dual therapy in patients with stage 2 hypertension.
Patients and methods
study design
This was a post hoc analysis of an eight-week, multicenter 
(75 centers in Europe and the United States), random-
ized, double-blind, parallel-group study. The methods are 
described in detail by Destro et al.17 After a three to seven-day 
washout period, all eligible patients (stage 2 hypertension 
[msSBP $ 160 mmHg and , 200 mmHg]) were randomized 
at baseline (week 0) to receive either Aml/Val 5/160 mg or 
Aml 5 mg for two weeks. After two weeks, the dose of Aml 
was force-titrated from 5 mg to 10 mg in both treatment arms. 
HCTZ 12.5 mg was added to both treatment groups at week 4 
(open-label), if the patient had not reached the pre-specified 
protocol criteria of msSBP , 130 mmHg.
All  patients  included  in  this  study  were  aged 
$18 years. Patients were excluded at screening if msSBP was   
,140 mmHg while receiving more than three antihyper-
tensive medications, or if msSBP was $140 mmHg and   
,180 mmHg while receiving more than two antihypertensive 
treatments, or if msSBP was $180 mmHg while receiving 
more than one antihypertensive medication. Patients with 
hepatic or renal impairment, secondary hypertension, clinically 
  significant cerebrovascular and cardiovascular disease, type 1   
diabetes, and inadequately controlled type 2 diabetes were 
also excluded.
Efficacy and safety assessments
Demographics and baseline characteristics of patients 
requiring HCTZ and those not requiring HCTZ at week 4 
were summarized. For the efficacy and safety analyses, only 
the subgroup of patients that required addition of HCTZ at 
week 4 were evaluated. The efficacy variables were change in 
msSBP and mean sitting diastolic blood pressure (msDBP) 
from baseline to week 8, week 4 to week 8, and overall BP 
control rate (,140/90 mmHg) at week 8. Because HCTZ was 
to be added if msSBP was $ 130 mmHg, patients included 
in the efficacy analyses may have an msSBP ,140 mmHg 
at week 4. To eliminate bias in assessing the effect of add-on 
HCTZ therapy on BP control at week 8, patients with BP   
,140/90 mmHg at week 4 were excluded from the control 
rate analysis. Subgroup analyses were also performed accord-
ing to the severity of hypertension (msSBP $ 180 mmHg 
at baseline), diabetic status, age group ($65 years), race 
(Caucasians and Non-Caucasians), and body mass index 
(BMI) $ 30 kg/m2.
At each visit, sitting BP were measured three times at 
two to three-min intervals using an Omron BP monitor 
(Omron Healthcare, Milton Keynes, UK) in accordance with 
the British Hypertension Society guidelines.18 BP readings 
were made by the same clinician whenever possible, at drug 
trough (ie, 24 ± 3 h post-dose). Safety assessments for this 
analysis consisted of a summary of AEs during week 4 to 
week 8 of treatment.
statistical analysis
Data gathered in this post hoc analysis was summarized 
with respect to demographic, efficacy, and safety variables. 
All efficacy analyses were conducted for the intent-to-treat 
population (randomized patients with a baseline and at least 
one post-baseline efficacy assessment).
Changes in msSBP and msDBP at week 8 were analyzed 
using analysis of covariance model with treatment and region 
as factors and baseline BP (week 0 or week 4 depending on 
analysis) as a covariate. The results were presented as least 
squares mean difference between the treatment groups with 
95% confidence interval and P value. The proportion of 
patients achieving BP control was analyzed using a logistic 
regression model, with treatment as factor and baseline BP as a 
covariate. Summary statistics were performed for further sub-
groups by age, gender, BMI, and severe SBP at baseline.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Results
Patient demographics and disposition
Of the patients randomized to Aml/Val (N = 322) and 
Aml (N = 324) treatment arms, 136 (42%) and 208 (64%), 
respectively, required add-on HCTZ, of whom 133 (98%) 
and 200 (96%) completed the study.
Demographic and baseline characteristics of patients 
requiring add-on HCTZ and those not requiring add-on 
HCTZ at week 4 are presented in Table 1. Compared to 
patients who did not receive add-on HCTZ, a greater percent-
age of patients requiring add-on HCTZ had diabetes (6.6% vs 
14.8%) and severe hypertension at baseline (13.6% vs 
18.0%). The baseline msBP of patients requiring add-on 
HCTZ (Aml/Val+HCTZ: 171.5/96.4 mmHg, Aml+HCTZ: 
171.5/95.0 mmHg) was numerically higher compared with 
patients who did not require add-on therapy (Aml/Val: 
169.3/95.1 mmHg, Aml: 169.8/94.1 mmHg). Within the 
patients who received add-on HCTZ, demographic and 
baseline characteristics were comparable between the two 
treatment groups.
Efficacy
The msSBP and msDBP of patients with week 4 HCTZ 
add-on therapy is plotted over time in Figure 1. For each 
post-baseline (week 0) measurement, patients belonging to 
Aml/Val+HCTZ triple therapy group achieved higher BP 
reduction than those in Aml+HCTZ dual therapy group, 
with an msBP of 141.2/82.2 mmHg vs 147.7/87.0 mmHg 
at week 8. An additional BP-lowering benefit was observed 
after the week 4 HCTZ add-on in both treatment groups. 
However, the incremental reduction from week 4 to week 8 
was significantly greater with HCTZ added to Aml/Val com-
pared with HCTZ added to Aml (6.9/3.5 vs 3.1/1.0 mmHg, 
P , 0.01) (Table 2).
The overall reduction from baseline to week 8 was also 
significantly greater in the Aml/Val+HCTZ triple com-
bination compared to Aml+HCTZ therapy (30.5/13.8 vs 
24.3/8.3 mmHg, P , 0.0001) (Table 2).
In patients not adequately controlled (BP . 140/90 mmHg) 
at week 4 on their existing medication, HCTZ 12.5 mg 
add-on for an additional four weeks facilitated attaining   
msBP , 140/90 mmHg in a higher proportion of patients 
previously on Aml/Val (37.7%) than Aml monotherapy 
(15.4%).
subgroups
Similarly greater reductions in msBP with Aml/Val+HCTZ 
triple therapy were observed in all the subgroups by severity 
of hypertension, diabetic status, age group, race, and BMI, 
compared with the reductions with Aml+HCTZ dual therapy 
(Figures 2a and 2b).
safety and tolerability
Both treatment arms were well tolerated. The overall 
  incidence of AEs was similar between the triple and dual 
Table 1 Baseline and demographic characteristics of patients requiring HCTZ and those not requiring HCTZ at week 4
Characteristics Patients not requiring HCTZ  Patients requiring add-on HCTZ
Aml/Val (N = 186) Aml (N = 116) Aml/Val+HCTZ (N = 136) Aml+HCTZ (N = 208)
Age ± sD (years) 57.5 ± 10.6 57.3 ± 10.8 58.8 ± 9.8 58.5 ± 10.2
Age category, n (%) 
  ,65 years 
  $65 years
 
137 (73.7) 
49 (26.3)
 
85 (73.3) 
31 (26.7)
 
98 (72.1) 
38 (27.9)
 
149 (71.6) 
59 (28.4)
gender, n (%) 
  Male 
 
94 (50.5)
 
51 (44.0)
 
71 (52.2)
 
108 (51.9)
Race, n (%) 
  caucasians 
  Blacks 
  Others
 
159 (85.5) 
6 (3.2) 
21 (11.3)
 
93 (80.2) 
2 (1.7) 
21 (18.1)
 
102 (75.0) 
15 (11.0) 
19 (13.9)
 
174 (83.7) 
10 (4.8) 
24 (11.6)
msSBP ± sD, mmHg 169.3 ± 8.6 169.8 ± 9.1 171.5 ± 9.2 171.5 ± 8.1
msDBP ± sD, mmHg 95.1 ± 9.5 94.1 ± 10.9 96.4 ± 10.4 95.0 ± 10.2
Hypertension severity  
at baseline, n (%) 
$180 mmHg
22 (11.8) 19 (16.4) 25 (18.4) 37 (17.8)
Diabetes; n (%)  13 (7.0) 7 (6.0) 22 (16.2) 29 (13.9)
BMI, Mean ± sD 28.9 ± 4.9 29.7 ± 5.9 31.1 ± 5.9 30.7 ± 5.6
Abbreviations: Aml/Val+HCTZ, amlodipine/valsartan+hydrochlorothiazide; Aml+HCTZ, amlodipine+hydrocholorothiazide; msSBP, mean sitting systolic blood pressure; 
msDBP, mean sitting diastolic blood pressure; BMI, body mass index; SD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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therapies (Table 3). Peripheral edema was the most frequently 
reported AE, which occurred at a slightly lower frequency 
in the presence of Val (Aml/Val+HCTZ: n = 19, 14.0%; 
Aml+HCTZ: n = 37, 17.8%).
Amongst patients who received HCTZ add-on at week 4, 
1.7% (n = 6) of patients discontinued the study prematurely 
(Aml/Val+HCTZ; 1.5% [n = 2], Aml+HCTZ: 1.9% [n = 4]) 
due to AEs. There were no deaths during the entire course of 
the study. Serious AEs were also not reported in any treat-
ment group from week 4 to week 8.
Discussion
Current hypertension treatment guidelines state that dual com-
bination therapy be considered as initial therapy in patients 
with msBP $ 20/10 mmHg above goal.1,2 Furthermore, recent 
outcome trials suggest that the percentage of patients requiring 
three or more antihypertensive drugs to achieve BP control 
can range from 23%−52% depending on the trial.5,14–16
In this study, patients with stage 2 hypertension were 
randomized to initiate therapy with either dual Aml/Val 
therapy or Aml monotherapy with the addition of HCTZ to 
either regimen if BP remained uncontrolled. Triple therapy 
with Aml/Val+HCTZ 10/160/12.5 mg provided clinically 
and statistically significant additional BP reductions com-
pared with the dual therapy with Aml+HCTZ 10/12.5 mg   
(P , 0.0001). Similarly, Aml/Val+HCTZ triple therapy 
produced greater BP reductions compared with Aml+HCTZ 
dual therapy in diverse patient populations, including patients 
regardless of age, diabetic status, BMI, or race. These results 
are consistent with those reported by Calhoun et al wherein 
triple therapy with Aml/Val/HCTZ at a dose of 10/320/25 mg 
was shown to have superior efficacy compared with Aml/
Val 10/320 mg, Val/HCTZ 320/25 mg, and Aml/HCTZ 
10/25 mg dual therapies in a parallel-design trial, where 
patients were randomized to the four treatment groups.19 The 
patients on triple therapy achieved a mean SBP reduction of 
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Figure 1 Mean msSBP and msDBP at each time point.
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Table 2 LSM difference in msSBP/DBP (intent-to-treat population)
N msSBP msDBP
LSM change (SEM) Difference (95% CI) LSM change (SEM) Difference (95% CI)
From baseline to week 8
Aml/Val+HCTZ  133 −30.5 (1.1) −6.1 (−8.6, −3.6)  
P , 0.0001
−13.8 (0.7) −5.5 (−7.1, −3.9)  
P , 0.0001 Aml+HCTZ  206 −24.3 (0.9) −8.3 (0.6)
From week 4 to week 8
Aml/Val+HCTZ  133 −6.9 (0.9) −3.8 (−6.1, −1.5)  
P = 0.0012
−3.5 (0.6) −2.6 (−3.9, −1.1)  
P = 0.0004 Aml+HCTZ  206 −3.1 (0.8) −1.0 (0.5)
Abbreviations: LSM, least squares mean; MSSBP, mean sitting systolic blood pressure; MSDBP, mean sitting diastolic blood pressure; Aml/Val+HCTZ, amlodipine/
valsartan+hydrochlorothiazide; Aml+HCTZ, amlodipine+hydrocholorothiazide; SEM, standard error of mean.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
825
Triple therapy for stage 2 hypertension
0
N3 62 4
SBP ≥ 180 SBP < 180 Diabetics Non-diabetics Obese Non-obese Caucasians Non-Caucasians Age < 65 yrs Age ≥ 65 yrs
170 110 29 22
Aml+HCTZ Aml/Val+HCTZ
177 112 97 68 109 66 173 101 33 33 147 96 59 38
−5
−10
−15
−20
−25
−30
−
3
1
.
4
−
2
2
.
2
S
B
P
 
c
h
a
n
g
e
 
(
m
m
H
g
)
−
2
3
.
8
−
3
8
.
0
−
2
8
.
5
−
2
8
.
2
−
2
3
.
8
−
2
1
.
6
−
2
0
.
1
−
2
2
.
8
−
2
9
.
0
−
2
4
.
2
−
2
2
.
6
−
3
0
.
5
−
3
0
.
5
−
2
9
.
8
−
2
8
.
8
−
3
4
.
4
−
3
1
.
5
−
2
6
.
8
−35
−40
A
Figure 2 Mean change from baseline to week 8 in msSBP (A) and msDBP (B) in subgroups.
Abbreviations: msSBP, mean sitting systolic blood pressure; msDBP, mean sitting diastolic blood pressure; Aml/Val+HCTZ, amlodipine/valsartan+hydrochlorothiazide; 
Aml+HCTZ, amlodipine+hydrocholorothiazide.
0
−2
−4
−6
−8
−10
−12
D
B
P
 
c
h
a
n
g
e
 
(
m
m
H
g
)
−14
−16
−18
−20
N3 62 4
SBP ≥ 180 SBP < 180 Diabetics Non-diabetics Obese Non-obese Caucasians Non-Caucasians Age < 65 yrs Age ≥ 65 yrs
170 110 29 22 177 112 97 68 109 66 173 101 33 33 147 96 59 38
−
1
0
.
4
−
7
.
3
−
6
.
3
−
8
.
0
−
6
.
1
−
6
.
4
−
6
.
8
−
1
3
.
2
−
8
.
4
−
6
.
4
−
1
6
.
8
−
1
3
.
4
−
1
5
.
4
−
1
3
.
8
−
1
3
.
6
−
1
4
.
5
−
1
2
.
8
−
1
7
.
8
−
1
4
.
9
−
1
1
.
8
Aml+HCTZ Aml/Val+HCTZ
BVascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
826
Destro et al
40–50 mmHg, which was clinically and statistically greater 
than that with the dual component therapies.19 In the pres-
ent study, a sequential antihypertensive treatment approach 
dependent on BP level achieved was followed, enabling the 
assessment of the efficacy and safety of adding a third agent 
in those patients initiated on dual therapy.
Hypertension is a multifactorial disease and the results 
of this study confirm that combining therapies with different 
mechanisms of action can additively reduce BP. Both Aml and 
Val are vasodilators that work through different mechanisms. 
Aml blocks calcium channels in vascular smooth muscle and 
Val blocks the binding of angiotensin II to the angiotensin type 
1 receptor. The antihypertensive efficacy of calcium channel 
blockers (CCBs), however, is reduced by the associated activa-
tion of the renin–angiotensin system (RAS) and the sympathetic 
nervous system.20 Coadministration of an angiotensin receptor 
blocker (ARB) can effectively prevent such responses.
In this study, the response to HCTZ was dependent on 
the initial treatment, ie, Aml/Val vs Aml. The benefit of add-
ing HCTZ was greater in patients treated with Val. This may 
be explained by the fact that diuretics decrease intravascular 
volume, activating RAS resulting in a diminished antihyper-
tensive response. This counter-regulatory effect is prevented in 
the presence of an ARB. In previous studies, Val and HCTZ in 
combination have demonstrated additional BP lowering effects 
compared with each of the component monotherapies.21,22 
While diminished efficacy of CCBs has been reported with 
concomitant diuretic therapy, other controlled studies have 
reported additional antihypertensive efficacy with a CCB and 
diuretic combination.23,24
Adding HCTZ to Aml/Val was not only effective in lower-
ing BP, but was also well tolerated. Treatment discontinua-
tions and the incidence of AEs were low with triple therapy 
and no difference was observed compared with dual therapy. 
The most frequently reported AE was peripheral edema, 
which appeared to be attenuated in the presence of Val.
Therapies combining drugs with complimentary mecha-
nisms of action have also been recommended because they may 
attenuate certain AEs like the peripheral edema associated with 
CCBs and the hypokalemia associated with thiazide diuretics.25,26 
For example, Val has previously been reported to reduce the inci-
dence of hypokalemia associated with HCTZ and the peripheral 
edema associated with Aml.21,27 Moreover, it has been suggested 
that combining different drugs in a single pill may lead to better 
compliance and hence better BP control.28,29
This study provides relevant information as it follows 
the clinical practice of prescribing a third antihypertensive 
agent in a step-wise manner to initial dual therapy depend-
ing on BP levels of the patient. The present analyses, 
however, have certain limitations: 1) this was a post hoc 
analysis of a study not designed to evaluate the efficacy 
of triple therapy vs dual therapy; 2) patients were not 
randomized to receive Aml/Val/HCTZ and Aml/HCTZ; 
and 3) the duration of the treatment with triple therapy 
was four weeks.
In conclusion, triple combination therapy with Aml/Val/
HCTZ provides significantly greater BP reductions and is well 
tolerated compared with Aml/HCTZ dual therapy in stage 2 
hypertension and can provide additional benefits in patients 
who require more than two agents to reach their target BP.
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Table 3 Frequent adverse events (AEs) $ 1% (safety population) 
in either treatment group
Event Aml/Val+HCTZ  
N = 136
Aml+HCTZ   
N = 208
Aes; n (%) 46 (33.8) 69 (33.2)
edema peripheral 19 (14.0) 37 (17.8)
nasopharyngitis 4 (2.9) 2 (1.0)
Headache 2 (1.5) 5 (2.4)
Dizziness 2 (1.5) 1 (0.5)
syncope 2 (1.5) 0 (0.0)
cough  1 (0.7) 4 (1.9)
Diarrhea  1 (0.7) 3 (1.4)
Viral infection 1 (0.7) 2 (1.0)
Paresthesia 0 (0.0) 2 (1.0)
Joint swelling 1 (0.7) 2 (1.0)
Dyspepsia 0 (0.0) 3 (1.4)
Flushing 0 (0.0) 3 (1.4)
Upper respiratory tract infection 0 (0.0) 2 (1.0)
Urinary tract infection 0 (0.0) 3 (1.4)
Hypokalemia 0 (0.0) 2 (1.0)
Arthralgia 0 (0.0) 2 (1.0)
neck pain 0 (0.0) 2 (1.0)
Abbreviations:  Aml/Val+HCTZ,  amlodipine/valsartan+hydrochlorothiazide; 
Aml+HCTZ, amlodipine+hydrocholorothiazide.Vascular Health and Risk Management
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